Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

65 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The influence of treatment sequence in the prognostic value of TMPRSS2-ERG as biomarker of taxane resistance in castration-resistant prostate cancer.
Marín-Aguilera M, Reig Ò, Milà-Guasch M, Font A, Domènech M, Rodríguez-Vida A, Carles J, Suárez C, Del Alba AG, Jiménez N, Victoria I, Sala-González N, Ribal MJ, López S, Etxaniz O, Anguera G, Maroto P, Fernández PL, Prat A, Mellado B. Marín-Aguilera M, et al. Among authors: anguera g. Int J Cancer. 2019 Oct 1;145(7):1970-1981. doi: 10.1002/ijc.32238. Epub 2019 Mar 23. Int J Cancer. 2019. PMID: 30807643
Tissue-based Biomarkers Steering Clinical Decisions in Patients with Urothelial Cancer.
Afferi L, Cimadamore A, Gallioli A, Pradere B, Mertens LS, Marcq G, Anguera G, Necchi A, Briganti A, Montorsi F, Rouprêt M, Gontero P, Breda A, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. Afferi L, et al. Among authors: anguera g. Eur Urol. 2024 Sep 11:S0302-2838(24)02573-9. doi: 10.1016/j.eururo.2024.08.033. Online ahead of print. Eur Urol. 2024. PMID: 39266382
Molecular characterization of chromophobe renal cell carcinoma reveals mTOR pathway alterations in patients with poor outcome.
Roldan-Romero JM, Santos M, Lanillos J, Caleiras E, Anguera G, Maroto P, García-Donas J, de Velasco G, Martinez-Montes ÁM, Calsina B, Monteagudo M, Letón R, Leandro-García LJ, Montero-Conde C, Cascón A, Robledo M, Rodriguez-Antona C. Roldan-Romero JM, et al. Among authors: anguera g. Mod Pathol. 2020 Dec;33(12):2580-2590. doi: 10.1038/s41379-020-0607-z. Epub 2020 Jul 2. Mod Pathol. 2020. PMID: 32616874 Free article.
Clinical Factors Associated With Long-Term Benefit in Patients With Metastatic Renal Cell Carcinoma Treated With Axitinib: Real-World AXILONG Study.
Pinto Á, Reig O, Iglesias C, Gallardo E, García-Del Muro X, Alonso T, Anguera G, Suárez C, Muñoz-Langa J, Villalobos-León L, Rodríguez-Sánchez Á, Lainez N, Martínez-Ortega E, Campayo M, Velastegui A, Rodriguez-Vida A, Villa-Guzmán JC, Méndez-Vidal MJ, Rubio G, García I, Capdevila L, Lambea J, Vázquez S, Fernández O, Hernando-Polo S, Cerezo S, Santander C, García-Marrero R, Zambrana F, González-Del Alba A, Lazaro-Quintela M, Castellano D, Chirivella I, Anido U, Viana A, García A, Sotelo M, Arévalo MG, García-Donas J, Hernández C, Bolós MV, Llinares J, Climent MA. Pinto Á, et al. Among authors: anguera g. Clin Genitourin Cancer. 2022 Feb;20(1):25-34. doi: 10.1016/j.clgc.2021.09.006. Epub 2021 Oct 20. Clin Genitourin Cancer. 2022. PMID: 34789409
Long-term Clinical Outcomes of a Spanish Cohort of Metastatic Renal Cell Carcinoma Patients with a Complete Response to Sunitinib.
de Velasco G, Alonso-Gordoa T, Rodríguez-Vida A, Anguera G, Campayo M, Pinto Á, Ortega EM, Gallardo E, Núñez NF, García-Carbonero I, Reig O, Méndez-Vidal MJ, Fernández-Calvo O, Cassinello NV, Torregrosa D, López-Martín A, Rosero A, Valiente PG, de España CG, Climent MA, Santasusana MD, Sánchez ÁR, González IC, Afonso R, García Del Muro X, Casinello J, Fernández-Parra EM, García Sánchez L, Afonso J, Polo SH, Asensio Ú. de Velasco G, et al. Among authors: anguera g. Clin Genitourin Cancer. 2023 Jun;21(3):e166-e174. doi: 10.1016/j.clgc.2022.11.021. Epub 2022 Dec 5. Clin Genitourin Cancer. 2023. PMID: 36610891
Deubiquitinase USP9X loss sensitizes renal cancer cells to mTOR inhibition.
Roldán-Romero JM, Valdivia C, Santos M, Lanillos J, Maroto P, Anguera G, Calsina B, Martinez-Montes A, Monteagudo M, Mellid S, Leandro-García LJ, Montero-Conde C, Cascón A, Roncador G, Coloma J, Robledo M, Rodriguez-Antona C. Roldán-Romero JM, et al. Among authors: anguera g. Int J Cancer. 2023 Sep 15;153(6):1300-1312. doi: 10.1002/ijc.34575. Epub 2023 Jun 1. Int J Cancer. 2023. PMID: 37260183
Cumulative incidences of hypogonadism, hypertension, and dyslipidaemia in patients with stage I seminoma treated with a risk-adapted strategy: a Spanish single-centre retrospective analysis.
Tapia JC, Gavira J, Anguera G, Sanchez S, Romano A, Bosma F, Molina A, Sanz-Beltran J, Martin-Lorente C, Algaba F, Maroto P. Tapia JC, et al. Among authors: anguera g. Clin Transl Oncol. 2024 Jul;26(7):1798-1803. doi: 10.1007/s12094-024-03393-9. Epub 2024 Feb 29. Clin Transl Oncol. 2024. PMID: 38421563
65 results